Integrated Testing Strategy for Skin Sensitisation

Allergic contact dermatitis (aka., skin sensitisation) accounts for 20% of all contact dermatitis cases and has an estimated annual cost of $200 million. It is also a public health problem, responsible for more than seven million outpatient visits annually. Currently, there are more than 3700 substances that are identified as contact allergens.

Douglas Connect provides an open implementation of the integrated testing strategy (ITS) that assesses skin sensitisation potency based on an approach developed at Proctor and Gamble.

The DC-ITS implementation combines information from three validated alternative assays (DPRA, KeratinoSens and h-CLAT) with in silico predictions for bioavailability using open cheminformatics tools from the community.

DC-ITS allows scientists to evaluate the skin sensitisation hazard of their chemicals using a combination of in vitro and in silico tools. It automatically compensates for the missing experimental data by using predicted values and utilizes the expert-knowledge embedded in the skin sensitization adverse outcome pathway (AOP). More

EwC CONNECTIONS